Transaction · 0001698262-26-000005
TVTXTravere Therapeutics, Inc.
Rote William E.
ROTE WILLIAM E., CRO, reported a transaction classified as exercise at Travere Therapeutics, Inc. involving 350.000000 shares for an estimated $6286.00. Reported holdings after the transaction were 98547.000000 shares. The stored filing text includes a detected 10b5-1 reference.
exerciseSEC transaction code MCRO
- Trade date
- Sep 16, 2026
- Filing date
- Sep 18, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
TVTX price since this filing
Daily closing prices, with the filing date and available return windowsTVTX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +1.2%1w ago +5.5%1d ago -0.4%
Returns since7d -5.3%30d -21.0%90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001698262-26-000005 Common Stock
- Transaction date
- Sep 16, 2026 Filed Sep 18, 2026, 01:35 AM · 2d delay
- Shares
- 350 sh $17.96 per share
- Estimated value
- $6.28k Computed from shares × price
- Holdings after
- 98,547 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership 10b5-1 Detected
Filing-only score
0 points
Compact filing score computed from stored Form 4 facts. Version v1.
Neutral filing signal
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
Chief Research Officer
Officer YesDirector No10% NoOther No
Footnotes & amended
- F1
Includes 271 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.
- F2
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F3
The weighted average sale price for the transaction reported was $61.994, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of…
- F4
The weighted average sale price for the transaction reported was $62.6552 and the range of prices were between $62.41 and $63.32. Upon request by the SEC staff, the Issuer, or any security holder of t…
- F5
The weighted average sale price for the transaction reported was $63.6508, and the range of prices were between $63.49 and $63.99. Upon request by the SEC staff, the Issuer, or any security holder of…
- F6
The weighted average sale price for the transaction reported was $63.1205, and the range of prices were between $62.47 and $63.4650. Upon request by the SEC staff, the Issuer, or any security holder o…
- F7
The weighted average sale price for the transaction reported was $63.6126, and the range of prices were between $63.47 and $63.96. Upon request by the SEC staff, the Issuer, or any security holder of…
- F8
The stock option is fully vested and exercisable.
Related transactions
Same SEC filing0 other transactions
Recent company activity
TVTX0 recent txs